Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMODITIES
2023-509891-40-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ambrisentan and tadalafil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of patients achieving low- or intermediate-low risk profile at 6 months. Planned start Aug 2025; status: authorised.
02
Drugs
ambrisentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-509891-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509891-40-00.